Section
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818
Urine biomarkers reflecting glomerular injury and tubular dysfunction can predict kidney function recovery after ambulatory acute kidney injury in hypertensive patients, aiding clinical decision-making during blood pressure management.
The OPTIMAS trial shows that chronic kidney disease does not alter the safety or efficacy of early direct oral anticoagulant use after acute ischemic stroke with atrial fibrillation, supporting early initiation regardless of kidney status.
A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant associati
Comparative review of angiotensin receptor blockers (ARBs, “沙坦”) and dihydropyridine calcium‑channel blockers (DHP‑CCBs, “地平类”) focused on organ protection—kidney, heart and brain—and practical selection based on comorbidity and evidence.
Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.
CKD-associated pruritus affects up to 85% of dialysis patients and significantly impairs quality of life. Stepwise management, including novel therapies like nemolizumab, is essential for effective symptom control and improved patient outco
